General Methods:
1 H-NMR spectra were recorded on a Bruker Avance (Billerica, MA) 400 (Newburyport, MA). All solvents used for reactions were distilled prior to use (THF over Na/benzophenone, CH 2 Cl 2 and CH 3 CN over CaH).
Preparative HPLC purifications were performed on an Agilent model 1100 (Santa Clara Flow rate = 6.5 mL/min.
Synthesis of Compounds 4-13.
Syntheses of compounds 4-9, and 11 have been previously reported. 1 Compounds 10, 12, and 13 are described below: 
S3

N-tert-Butyloxycarbonyl-L-alanyl-D-[p-(benzyloxy)phenyl]glycine
S4
N-tert-Butyloxycarbonyl-D-[p-(benzyloxy)phenyl]glycyl-L-alanyl-D-[p-(benzyloxy)-
phenyl]glycine Benzyl Ester (S4).
The title compound was prepared and purified analogously to compound S2 by replacing S1 with S3 in the procedure. The product
was obtained as an amorphous solid (2.37 g, 81% 
D-[p-(Hydroxy)phenyl]glycyl-L-alanyl-L-[p-(hydroxy)phenyl]glycyl-pantetheine (10).
To a 250 mL pressure flask, protected tripeptide S2 (568 mg, 0.75 mmol) was dissolved in 20 mL of reagent grade THF and to this solution was added a catalytic amount of Pd-OH/C. The mixture was vigorously shaken under 50 psi of H 2 overnight on a Parr hydrogenation apparatus. The mixture was filtered through Celite, which was washed with 100 mL of THF and concentrated in vacuo to a white foam and used in the next step without further purification.
To a 25 mL round-bottomed flask equipped with a magnetic stir bar, the freshly deprotected tripeptide was dissolved in 5 mL of reagent grade DMF. chloroeremomycin (CepCTE) 5 and TE cyclase domains from gramicidin S (GrsTE), 6, 7 tyrocidine (TycTE), 8 fengycin (FenTE) 9 and surfactin (SrfTE) 10 . The positions of the catalytic triad residues (Ser, His, Asp) are highlighted with arrows. Sequence alignment performed using CLUSTAL X. ......10........20........30........40........50........60........70........80........90.. ...110.......120.......130.......140.......150.......160.......170.......180.......190.. 
